SEARCH

SEARCH BY CITATION

References

  • Bishop, J.F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M., Fox, R., Cobcroft, R., Herrmann, R., Van Der Weyden, M., Lowenthal, R.M., Page, F., Garson, O.M. & Juneja, S. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 17101717.
  • Broxterman, H.J., Sonneveld, P., Van Putten, W.J., Lankelma, J., Eekman, C.A., Ossenkoppele, G.J., Pinedo, H.M., Lowenberg, B. & Schuurhuis, G.J. (2000) P-glycoprotein in primary acute myeloid leukaemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia, 14, 10181024.
  • Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R. & Keating, M.J. (1990) Report of the National Cancer Institute–sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology, 8, 813819.
  • Haferlach, T., Kern, W., Schoch, C., Schnittger, S., Sauerland, M.C., Heinecke, A., Buchner, T. & Hiddemann, W. (2004) A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica, 89, 408418.
  • Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and a long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 6470.
  • Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, F.R. & Whillman, C.L. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 10861099.
  • Russo, D., Malagola, M., De Vivo, A., Fiacchini, M., Martinelli, G., Piccaluga, P.P., Damiani, D., Candoni, A., Michielutti, A., Castelli, M., Testoni, N., Ottaviani, E., Rondoni, M., Pricolo, G., Mazza, P., Zuffa, E., Zaccaria, A., Raspadori, D., Bocchia, M., Lauria, F., Bonini, A., Avanzini, P., Gugliotta, L., Visani, G., Fanin, R. & Baccarani, M. (2005) Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 131, 172179.
  • Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Karl, S., Theil, A.M., Paietta, E., Whillman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 40754083.
  • Staib, P., Staltmeier, E., Neurohr, K., Cornely, O., Reiser, M. & Schinkothe, T. (2005) Prediction of individual response to chemotherapy in patients with acute myeloid leukemia using the chemosensitivity index Ci. British Journal of Haematology, 128, 783791.